System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Hakim Mahammedi is an expert in Oncology at Centre Jean Perrin (France). As of October 2026, ScienceLeadR ranks Hakim Mahammedi in the top 1% of experts worldwide for Prostatic Diseases, Urogenital Neoplasms and Genital Diseases, Male. Hakim Mahammedi has authored 93 publications, the most recent in 2026, and is an investigator in 45 clinical trials, 25 of them ongoing. SLR score: 873 (community average: 125). How the SLR is computed.

LeadR Profile

Hakim Mahammedi Centre Jean Perrin France
873 ScienceLeadR Reputation 873

Unlock

Register Login
Network Map

Oncology

Subspecialties: Urology - Public Health - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2011 - 2026
Source: PubMed

Centre Jean Perrin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 93

Citations

Citations: 8 592 1st author: 4 Last author: 5 Unique author: 0

Main journals

J Clin Oncol 24
Ann Oncol 10
MED NUCL 6
N Engl J Med 6
Eur Urol 5

Best Journals

J Clin Oncol 17
Ann Oncol 8
N Engl J Med 6

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
[ 177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.
PMID 42561994 — safety, progression-free survival, androgens, neoplasms, prostate, drug-related side effects and adverse reactions, prostatic neoplasms, therapeutics		Lancet Top journal20266
Squamous Cell Carcinoma of the Bladder: Current Evidence, Therapeutic Challenges, and Research Perspectives from the French AVENTUR Group.
PMID 42520864 — urinary bladder, urinary bladder neoplasms, cells, epidemiology, carcinoma, squamous cell, neoplasms, immunotherapy, research, therapeutics, hematologic diseases		Crit Rev Oncol Hematol20260
Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.
PMID 42177701 — safety, drug therapy, immunotherapy, therapeutics, chemotherapy		Cancer Immunol Immunother20260
Preventive Behaviors of French Cancer Patients and How They Changed During the COVID-19 Outbreak (PAPESCO-19 Study).
PMID 41409884 — neoplasms, public health, covid-19		Int J Public Health20250
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study.
PMID 41224576 — cells, genes, urology, vascular endothelial growth factor a, lymphocytes, carcinoma, renal cell, biomarkers, nivolumab, tissues, gene expression		Eur Urol20250

Clinical Studies 45

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4

By phase:

Phase 3 25
Phase 2 13
Phase 1/Phase 2 3
Phase 2/Phase 3 2
N/A 1
Phase 4 1

By status:

Recruiting 19
Active not recruiting 12
Completed 11
Unknown 2
Terminated 1

By type:

Interventional 45

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 4
multicentricup10 38

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

25 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
CARE1 FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
2023-503317-29-00 — cells, carcinoma, renal cell, therapeutics, carcinoma		Phase 3Recruiting2024
A clinical trial to learn about the effects of AMO959 given with AAA617 and an androgen receptor pathway inhibitor (ARPI) in adults with PSMA positive prostate cancer that has spread to other parts of the body pathway inhibitor (ARPI) in adults with PSMA positive prostate cancer that has spread to other parts of the body
2025-521859-23-00 — protein kinases, androgens, receptors, androgen, neoplasms, multiple chronic conditions, prostate, protein kinase inhibitors, prostatic neoplasms, castration, dna		Phase 1/Phase 2Recruiting2026
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator s Choice in Chemotherapy na ve Metastatic Castration resistant Prostate Cancer
2025-520555-89-00 — neoplasms, prostate, drug therapy, prostatic neoplasms, castration, therapeutics, chemotherapy		Phase 3Recruiting2025
A clinical trial of sacituzumab tirumotecan to treat urothelial cancer (MK 2870 031)
2024-520014-22-00 — neoplasms, drug therapy, chemotherapy, carcinoma		Phase 3Recruiting2026
A Phase 3 Study Comparing BMS 986365 versus Investigator s Choice of Therapy in Participants with Metastatic Castration resistant Prostate Cancer
2024-517422-25-00 — docetaxel, androgens, receptors, androgen, neoplasms, prostate, prostatic neoplasms, castration, therapeutics		Phase 3Active not recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS